East India Pharmaceutical Works Limited Unlisted Share Price
East India Pharmaceutical Works Limited unlisted share price is ₹79 per share (indicative, as of 17 Oct 2026). Minimum ticket ₹25,000 (lot of 320 shares), the same for every company. Sector: Consumer. Status: unlisted, no DRHP on record.
All unlisted share prices: dated indicative prices for every company the desk tracks.
Updated 17 Oct 2026, 22:10 IST. Dated dealer references.
BuyUnlistedShares tracks 230 unlisted companies with dated prices; East India Pharmaceutical Works Limited’s indicative price is ₹79 per share as of 17 Oct 2026, a lot of 320 shares.
Key facts
- Indicative price
- ₹79 per share
- Price as of
- 17 Oct 2026
- Minimum investment
- ₹25,000
- Lot size
- 320 shares
- Sector
- Consumer
- Listing status
- Unlisted
- Settlement
- Demat to demat; terms agreed in writing for each deal
- Last updated
- 17 Oct 2026, 22:10 IST
Indicative and dated. BuyUnlistedShares deals as principal.
Buying at a glance
- Minimum ticket
- ₹25,000
- Price shown
- Indicative, dated 17 Oct 2026
- Delivery
- Shares are credited to your demat account
In plain words
- Lock-in if it lists
- Shares bought before an IPO are generally locked in for six months from the IPO allotment date under SEBI rules. The issue documents set the exact terms.
- Demat
- Yes. ISIN INE254X01017: the shares sit in your own demat account and move demat to demat through NSDL or CDSL.
- IPO status
- Unlisted. No DRHP on record.
Facts only, not a rating or a recommendation.
Compare it against the full unlisted share price list: every company the desk quotes, each with a dated indicative price.
Indicative quote unchanged since 25 Jun 2026 (116 dated quotes); no price movement to chart yet.
Key figures
| Market cap | ₹53 Cr |
|---|---|
| Minimum investment | ₹25,000 |
| Lot size | 320 |
| P/E ratio | 23.87x |
| ROE | 3.82% |
| Book value | ₹86.69 |
| Face value | ₹10 |
| 52-week high | ₹79 |
| 52-week low | ₹79 |
| ISIN | INE254X01017 |
| Dividend yield | — |
Financials (₹ Cr)
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 234 | 250 | 272 |
| PAT | 1.69 | 3.87 | 2.21 |
| EPS (₹) | 2.53 | 5.80 | 3.31 |
About the company
East India Pharmaceutical Works Limited is one of India's oldest pharmaceutical companies, incorporated in 1936 and headquartered in Kolkata, West Bengal. Over more than eight decades, the company has built a presence in the domestic healthcare market through the manufacturing and marketing of a broad range of formulations spanning analgesics, haematinics, digestive enzymes, eye-care products…
Prices shown are indicative and dated. Unlisted shares are illiquid and values can move sharply.
Registered in Kolkata, West Bengal.
Registry
- ISIN: INE254X01017
- Depository: NSDL & CDSL
- Listed at: Unlisted
- Price as of: 17 Oct 2026
Company facts
| CIN | U24231WB1936PLC008598 |
|---|---|
| Incorporated | 1936 |
| ISIN | INE254X01017 |
| Face value | ₹10 |
| Registered office | 6, Nandalal Bose Sarani, Kolkata - 700071 |
| Lot size | 320 shares |
| Minimum units | 130 |
| DRHP | Not filed |
Financial statements (₹ Cr)
| Metric | FY22 | FY23 | FY24 | FY25 | FY25 vs FY24 |
|---|---|---|---|---|---|
| Revenue | 202.5 | 233.77 | 249.94 | 271.84 | +8.8% |
| EBITDA | — | 10 | 12.4 | 13 | +4.8% |
| Profit before tax | — | 2.4 | 4.5 | 4 | −11.1% |
| Profit after tax | 4.5 | 1.69 | 3.87 | 2.21 | −42.9% |
| EPS (₹) | 6.74 | 2.53 | 5.8 | 3.31 | −42.9% |
| Operating margin | — | — | 4.5% | 4.4% | −0.1 pts |
| Net margin | — | — | 1.6% | 0.8% | −0.7 pts |
| Share capital | — | 6.67 | 6.67 | 6.67 | +0% |
| Reserves & surplus | — | 46.04 | 49.44 | 51.15 | +3.5% |
| Net worth | — | 52.71 | 56.11 | 57.82 | +3% |
| Trade receivables | — | — | 122.74 | 148.68 | +21.1% |
| Trade payables | — | — | 49.77 | 63.72 | +28% |
| Cash from operations | — | — | 2.33 | 6.19 | +165.7% |
| Cash from investing | — | — | −1.12 | −2.83 | −152.7% |
| Cash from financing | — | — | −2.9 | −0.46 | +84.1% |
| Net cash generated | — | — | −1.69 | 2.9 | loss to profit |
Key ratios and valuation
| Measure | Value | Basis |
|---|---|---|
| Indicative price | ₹79 | dealer reference, 17 Oct 2026 |
| Market cap | ₹53 Cr | as recorded |
| P/E | 23.87x | price ÷ EPS ₹3.31 (FY25) |
| P/B | 0.91x | price ÷ book value ₹86.69 |
| EPS | ₹3.31 | per share, FY25 |
| Book value | ₹86.69 | per share, latest books |
| RoE | 3.82% | return on equity, latest FY |
| Debt / equity | 0.92 | latest balance sheet |
| Dividend yield | — | |
| Face value | ₹10 | per share |
| 52-week range | ₹79 (unchanged) | quote unchanged since 25 Jun 2026 |
| Shares outstanding | — | not meaningful |
Shareholding pattern
| Category | Holder | % of equity |
|---|---|---|
| Promoters | Promoters | 92.83% |
| Public | Public | 4.1% |
| Others | Others | 3.07% |
Promoters 92.83% · Public 4.1% · Others 3.07%
Management and promoters
| Name | Designation | Experience |
|---|---|---|
| Satarupa Mukherjee | Managing Director | — |
| Sanghamitra Duttagupta | Managing Director / Director | — |
| Debarshi Duttagupta | Managing Director | — |
| Indrani Sen | Director | — |
| Trishna Guha | Director | — |
| Ajoy Krishna Chatterjee | Director | — |
| Shibu Das | Director | — |
| Probir Roy | Director | — |
| Sukamal Chandra Basu | Director | — |
| Tapas Raychaudhury | Director | — |
| Abhijit Banerjee | Director | — |
Business model
East India Pharmaceutical Works Limited is a pharmaceutical manufacturer established in 1936. It operates WHO-GMP compliant manufacturing facilities at Sarsuna and Durgapur and sells into domestic and select international markets. Its product portfolio includes analgesics, antibiotics, hematinics, vitamins, gastrointestinal medicines and Ayurvedic formulations. The FY25 management report says its strategy included expanding marketing reach and launching products in multivitamin and paediatric segments.
It reported stable domestic revenue from demand for modern and Ayurvedic products, increased capacity utilisation at its Durgapur bulk-drug unit, and digital engagement with healthcare professionals. The company says it focuses on product quality, regulatory compliance and cost optimisation through backward integration of APIs. Its operating system includes ERP across inventory, production and sales, GMP-compliant manufacturing and quality-assurance protocols, and automated management information systems.
The company reports employing more than 1,500 people across plant operations, quality assurance, marketing and management.
Corporate actions and events
| Date | Type | Detail | Ratio / amount | Source |
|---|---|---|---|---|
| Undated | Agm | At the 87th AGM, shareholders approved Debarshi Duttagupta's appointment as Managing Director for three years from 1 September 2024. (20 Sep 2024) | — | Desk note |
| Undated | Other | The Board appointed Probir Roy as Chairman. (12 Dec 2024) | — | Desk note |
| Undated | Other | The Board appointed Shibu Das (DIN 00335520) as a director in a casual vacancy. (7 Mar 2025) | — | Desk note |
Reports and filings
No filings uploaded yet.
Annual reports
- East India Pharmaceutical Works Limited annual report 2024-25 (PDF)
- East India Pharmaceutical Works Limited annual report 2023-24 (PDF)
- East India Pharmaceutical Works Limited annual report 2022-23 (PDF)
- East India Pharmaceutical Works Limited annual report 2021-22 (PDF)
Frequently asked questions
What does East India Pharmaceutical Works Limited do?
East India Pharmaceutical Works Limited is a Kolkata-headquartered pharmaceutical company, incorporated in 1936. It manufactures and markets a range of healthcare products across segments such as analgesics, haematinics, digestive enzymes, eye care, and anti-infectives, alongside select Ayurvedic and personal-care lines, using both in-house and contract manufacturing.
Is East India Pharmaceutical Works Limited listed on NSE or BSE?
No. East India Pharmaceutical Works Limited is currently an unlisted company and its shares are not traded on the NSE or BSE. Its shares are dealt with in the unlisted market, where any quoted price is indicative rather than determined by a stock exchange.
How can I buy East India Pharmaceutical Works Limited unlisted shares?
Unlisted shares are transferred privately rather than through an exchange. For information on availability, the transfer process, and current indicative pricing, you can contact the desk, who can explain how such transactions are typically handled.
What are the risks of holding East India Pharmaceutical Works Limited unlisted shares?
Unlisted and pre-IPO shares carry higher risk and lower liquidity than listed equities. They may be difficult to sell quickly, any quoted price is indicative and can move sharply, public disclosures may be limited, and there is no certainty that the company will list. Individuals should conduct their own due diligence and consider their personal circumstances.
What is the East India Pharmaceutical Works Limited unlisted share price today?
The indicative over-the-counter reference price is ₹79 per share as of 17 Oct 2026. It is a dated dealer reference, refreshed every working day.
Is East India Pharmaceutical Works Limited listed on a stock exchange?
Not yet. East India Pharmaceutical Works Limited changes hands in the unlisted market, over the counter and settle into your demat account through NSDL and CDSL.
What is the minimum investment in East India Pharmaceutical Works Limited?
The minimum ticket is ₹25,000, the same for every company on the site.
What is the ISIN of East India Pharmaceutical Works Limited?
INE254X01017. Holdings are settled in demat form through NSDL and CDSL.
How do I buy East India Pharmaceutical Works Limited unlisted shares?
Send an enquiry with the quantity you have in mind. The desk replies with a dated quote, the paperwork list and the demat steps, and the shares settle demat to demat into your own account.
Is there a lock-in if East India Pharmaceutical Works Limited lists?
Pre-IPO shareholders other than promoters are generally locked in for six months from the date of IPO allotment under SEBI ICDR regulation 17. The final offer document sets the exact terms.
Sources
- East India Pharmaceutical Works Limited annual report 2024-25 · FY 2024-25 · eastindiapharma.org
- East India Pharmaceutical Works Limited annual report 2023-24 · FY 2023-24 · eastindiapharma.org
- East India Pharmaceutical Works Limited annual report 2022-23 · FY 2022-23 · eastindiapharma.org
- East India Pharmaceutical Works Limited annual report 2021-22 · FY 2021-22 · eastindiapharma.org
- BuyUnlistedShares indicative price series for East India Pharmaceutical Works Limited, dated daily · since 25 Jun 2026 (114 dated quotes) · buyunlistedshares.com
How to cite this page: BuyUnlistedShares, “East India Pharmaceutical Works Limited unlisted share price”, https://buyunlistedshares.com/unlisted-shares/east-india-pharmaceutical-works-limited, as of 17 Oct 2026.
Other Consumer unlisted shares
- A V Thomas & Co. Limited · ₹12,500
- Anglo French Drugs and Industries · ₹1,075
- Anheuser Busch Inbev India (AB InBev) · ₹555
- Apollo Fashion International · ₹44
- Arch Pharmalabs Limited · ₹85
- Auckland Jute Co. Limited · ₹189
Enquire to buy East India Pharmaceutical Works Limited · Sell a holding
Indicative reference price, dated. BuyUnlistedShares is India's premium unlisted shares desk, run by Gayatri Financial Synergy LLP. In the market since 2002. Data as of 17 Oct 2026.
Before you buy: guides
- How to evaluate an unlisted company before investing
- How Unlisted Share Prices Are Discovered When There Is No Live Order Book
- The risks of buying unlisted and pre-IPO shares in India
- Unlisted Shares Lock-In Period: What Every Investor Must Know (2026)
- Can an NRI invest in unlisted shares in India?
All unlisted shares · IPO calendar · Research & learning · Send an enquiry · Calculators · Jobs · About · Contact · Privacy · Terms · Disclaimer · Grievance redressal
Guides: Start investing · Evaluate a company · How prices are set · Risks · Lock-in periods · After the IPO · Sell ESOPs · NRI investors · Buybacks · Choosing a platform
BuyUnlistedShares (BUS) · Gayatri Financial Synergy LLP (LLPIN ACU-4678) · SCO-39, 1st Floor, HUDA Market, Sector-7, Faridabad, Haryana 121006 · +91 916-916-59-59
